LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology
Ballerup, April 9, 2019: LEO Pharma A/S, a global leader in medical dermatology and Elektrofi, a Boston- based biotechnology company focused on drug formulation and delivery innovations, today announced an expansion of the two companies’ partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology.
As part of the agreement LEO Pharma and Elektrofi will initially co-develop two specific anti-bodies. The agreement includes an option to a pre-negotiated license for the potentially improved antibodies in the pre-clinical and clinical stage. LEO Pharma and Elektrofi will work closely together in an alliance to enable a lower injection volume for subcutaneous administration and, in turn, enable novel formulations and better convenience for patients.
“At LEO Pharma we are working constantly to find innovative ways to help people with skin diseases and improve their quality of life. Together with Elektrofi, we hope to find new, more convenient solutions for drug delivery, which potentially will be of benefit to patients,” said Kim Kjøller, executive Vice President, Research & Development, LEO Pharma.
“We are excited to further our partnership with LEO Pharma, who we consider to be a leader in patient centric innovation. This flagship deal for our growing company is an exciting consummation of a close partnership over the last 2 years. The biopharma industry’s continued shift to subcutaneous administration is a reflection of patients’ demand for convenience. Elektrofi is thrilled to utilize its technology with LEO Pharma to improve patients’ lives,” said Jason Norris, Cofounder, Elektrofi.
About Elektrofi’s technology: Elektrofi leverages its microparticle suspension formulation technology (ElektrojectTM) to enable syringe-compatible injections of high-dose antibody therapeutics. Most antibody solutions are unusable in syringes at high concentrations due to concentration associated syringe forces that exceed human ability, leaving drug developers to either increase dose frequency or administer prolonged, large-volume infusions. ElektrojectTM suspensions enable clinicians and patients to administer high doses of antibody therapies in a relatively small volume within seconds in addition to providing improved product stability at full quality.
Jason Norris, Cofounder
LEO Pharma A/S
Trine Juul Wengel
Tel.: +45 20732037
Information om LEO Pharma
Elektrofi is a biotechnology company headquartered in Boston, MA, USA working on transforming the delivery of biologics. We envision a patient-centric future where all protein therapeutics can be conveniently administered to patients in small-volume syringe injections instead of large-volume intravenous infusions or frequent injections. Elektrofi’s gentle platform technology, ElektrojectTM, enables the transformation to high-dose subcutaneous delivery without compromise on product quality for a wide-range of biologics. For more information, please visit www.elektrofi.com or send a message to
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
For more information, go to: www.linkedin.com/company/leo-pharma or www.leo-pharma.com
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases11.4.2019 11:40:51 CEST | Pressemeddelelse
The large-scale IMI project will investigate the causes and mechanisms of Atopic Dermatitis and Psoriasis
LEO Pharma A/S and LTS Lohmann Therapie-Systeme AG initiate first-ever clinical trial of microarray patches for psoriasis treatment19.3.2019 10:33:23 CET | Pressemeddelelse
Andernach, DE, and Ballerup, DK, March 19, 2019: LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma A/S, a global leader in dermatology, today announced that the companies will start the clinical trial of microarray patches for the local intradermal treatment of psoriasis. The study will start in April 2019 with expected completion later this year and the aim of the study is to document safety and efficacy in patients.
Olivier Bohuon elected new chairman of LEO Pharma’s Board of Directors28.2.2019 00:10:03 CET | Pressemeddelelse
BALLERUP, Denmark, 28 February 2019 – LEO Pharma today announced changes to its Board of Directors. Olivier Bohuon is announced new chairman of the Board of Directors succeeding Jukka Pertola, who has decided to leave the Board. Member of the Board Anders Ekblom will assume a new position as vice chairman. In addition, John Weeks decided to not seek re-election.
LEO Pharma Annual Results 2018: A year in line with expectations28.2.2019 00:08:59 CET | Pressemeddelelse
- 2018 revenue of DKK 10,410 million - Strong progress on 2025 Strategy - Strengthened innovative clinical pipeline - Expanded established portfolio
Forskere fra LEO Pharma hyldes med Innovationsfondens Innovatørpris 20191.2.2019 15:01:40 CET | Pressemeddelelse
Excellent og banebrydende forskning, som skaber værdi for Danmark, er i fokus, når Innovationsfonden i dag uddeler årets priser. Det er derfor med stor stolthed, at LEO Pharma i dag kan meddele, at to af virksomhedens forskere, Marianne Lind, Ph.d. Senior Scientist og Karsten Petersson, Ph.d. Director, er udvalgt til at modtage Innovatørprisen 2019. Det er tredje år i træk, at prisen uddeles, og tildelingen af årets Innovatørpris til Marianne Lind og Karsten Petersson, som begge arbejder inden Explorative Formulation & Technologies hos LEO Pharma, sker på baggrund af følgende vurderinger: Den værdiskabelse, kandidaterne har skabt for såvel virksomhed som patienter Kandidaternes evne til at omsætte excellent forskningsviden til konkrete løsninger De to forskere modtager prisen for udviklingen af Enstilar®, LEO Pharmas skumspray til behandling af psoriasis. Enstilar® blev godkendt af Lægemiddelstyrelsen og kom på markedet i Danmark i 2016. Produktet anvendes i dag af flere end en million
LEO Pharma further Boosts Focus on Translational Medicine with the Appointment of Thomas Hultsch, M.D., Ph.D., as Head of Translational Medicine28.1.2019 10:15:51 CET | Pressemeddelelse
Ballerup, Denmark, 28 January, 2019 – LEO Pharma, a global leader in medical dermatology, today announced that Thomas Hultsch, M.D., Ph.D., has been appointed as Head of Translational Medicine as of 28 January, 2019.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum